There is a significant lack of dedicated randomized controlled trial evidence to guide percutaneous coronary intervention and antithrombotic therapy in patients with chronic kidney disease.
Clinicians should individualize PCI decisions in CKD amid sparse evidence; leaves open the urgent need for dedicated randomized trials.
that included patients with CKD, only four (3%) reported a subgroup analysis of treatment stratified by renal dysfunction [6]. As a result, few data exist from RCTs to guide decisions concerning PCI in patients with CKD. The majority of our evidence in this patient subset comes from observational registries or post hoc subgroup analysis of RCTs. The presumption of similar efficacy of PCI and the concomitant use of antithrombotic adjuncts in patients with CKD is challenging given the known differences in the pathophysiology of cardiovascular disease in these patients and their well-recognized qualitative platelet a bnormalities and coagulation d isorders [7].
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: